论文部分内容阅读
目的:观察尿激酶联合利福平腹腔注射治疗青海高海拔地区结核性腹膜炎患者的疗效。方法:选取2014年1月—2015年12月于我院接受治疗的86例结核性腹膜炎患者作为研究对象,随机分为对照组及观察组,每组43例,所有患者均给予口服抗结核药物、营养支持、腹腔抽液等基础治疗。在此基础上,对照组给予利福平腹腔注射治疗,观察组给予尿激酶联合利福平腹腔注射治疗。记录并比较两组患者腹水消退时间、腹痛消失时间、治疗9个月后腹膜厚度、腹膜粘连发生率以及治疗前后腹水IFN-γ、ADA、CA125水平及治疗期间不良反应发生情况。结果:与对照组相比,观察组患者腹水消失时间、腹痛消失时间缩短,治疗9个月后腹膜厚度减小、腹膜粘连发生率降低,治疗后腹水IFN-γ、ADA、CA125水平明显降低,差异有统计学意义(P<0.05);两组患者之间不良反应发生率无明显差异(P>0.05)。结论:尿激酶联合利福平腹腔注射治疗青海高海拔地区结核性腹膜炎患者疗效显著,值得临床推广使用。
Objective: To observe the curative effect of urokinase combined with rifampicin intraperitoneal injection on patients with tuberculous peritonitis at high altitude in Qinghai. Methods: Totally 86 patients with tuberculous peritonitis who were treated in our hospital from January 2014 to December 2015 were selected and randomly divided into control group and observation group, with 43 cases in each group. All patients were given oral anti-tuberculosis drugs , Nutritional support, abdominal pumping and other basic treatment. On this basis, the control group was given intraperitoneal injection of rifampicin, the observation group was given intraperitoneal injection of urokinase combined with rifampicin. The time of ascites extinction, the disappearance of abdominal pain, the peritoneal thickness and the incidence of peritoneal adhesions after 9 months of treatment and the levels of ascites IFN-γ, ADA and CA125 before and after treatment were recorded and compared. The incidence of adverse reactions during the treatment were recorded and compared. Results: Compared with the control group, the disappearance time of ascites and the disappearance of abdominal pain in the observation group were shortened. After 9 months of treatment, the peritoneal thickness and the incidence of peritoneal adhesions decreased. The levels of IFN-γ, ADA and CA125 in the ascites decreased significantly after treatment, The difference was statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: Urokinase combined with rifampicin intraperitoneal injection treatment of tuberculosis peritonitis in Qinghai high altitude patients with significant effect, worthy of clinical promotion and use.